A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China (ADDRESS)
A Prospective, National, Multi-center, Non-intervention Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
A observational or N/A phase clinical study on NSCLC, Stage I and NSCLC, Stage II, this trial is completed. The trial is conducted by The First Affiliated Hospital of Guangzhou Medical University and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Aug 2025 — Sep 2025 [monthly]
Completed
Status: Unknown → Completed
-
Sep 2024 — Aug 2025 [monthly]
Unknown
-
Aug 2024 — Sep 2024 [monthly]
Unknown
Status: Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
May 2021 — Jul 2024 [monthly]
Recruiting
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital of Guangzhou Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anyang, China , Beijing, China , Cangzhou, China , Changchun, China , Changsha, China , Chengdu, China , Chifeng, China , Chongqing, China , Dalian, China , Fuzhou, China and 22 more locations